

9/10/2020



FOR INTERNAL USE ONLY

Executive Summary

Updated: 03 August 2020



- A. Licensed countries (i.e. countries with regulatory approval):
- 29 countries with formal reimbursement in Europe
- ${\bf 41}$ countries with formal reimbursement at ${\bf Global}$ level
- B. NPP and/or individual patient reimbursed countries:
- 6 countries in Europe
- 17 countries at Global level
- C. Total Access (Global)
- 58 countries world-wide where we have achieved formal reimbursement, individual reimbursement, or a named-patient sales program

 - Formal reimbursement: 41 countries
 Individual patient request reimbursement: 7 countries
 Named-patient sales program (NPP): 10 countries

FOR INTERNAL USE ONLY

&R	Reimbursement Status	Countries (71)
œK.	Reimbursement Status	Countries (71)
	Full reimbursement (as per label)	[22] Germany, Italy, Luxembourg, Israel, Japan, Spain, Belgium, Romania, Hong Kong, Portugal, Poland, Scotland, Slovenia, France, UK (England/Wales), UK (N. Ireland), Qatar, UAE, Croati-Brazil, Netherlands ² , Czech Republic
	Broad reimbursement (in line or broader than clinical trial data)	[16] USA, Greece, Sweden, Norway, Hungary, Switzerland, Finland, Australia, Slovakia, Iceland, S. Korea, Argentina ⁹ , Austri Canada ³ , Ireland, Bulgaria
<u></u>	Restricted Reimbursement (whilst negotiations ongoing)	[3] Denmark ¹ , Latvia ⁵ , Taiwan ⁸
	Individual Reimbursement	[7] Chile, Cyprus, Lithuania, Uruguay, Mexico <i>(private insurance)</i> Colombia, Russia ⁷
	Named Patient Sales Program (NPP)	[10] Turkey, S. Arabia, Kuwait, Serbia, Macau, Montenegro, Egyp Oman, North Macedonia, Costa Rica
	Negotiations underway	[5] Estonia, New Zealand, Bahrain, Singapore, China ⁴
	Preparations underway	[8] Ukraine, Algeria, Malaysia, Iraq, Ecuador, Guatemala, Panam Peru

